GSK1363089 (formerly XL880)

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Neoplasms, Gastrointestinal TractSolid Tumours

Phase 1

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

CompletedNCT00743067

GlaxoSmithKlineSolid Tumours

Start: 2006-08-09End: 2009-11-09Updated: 2017-07-26

Phase 2

Study of GSK1363089 in Metastatic Gastric Cancer

CompletedNCT00725712

GlaxoSmithKlineNeoplasms, Gastrointestinal Tract

Start: 2007-03-31End: 2009-11-30Updated: 2017-08-24